The FDA has raised new doubts about Capricor Therapeutics’ treatment for Duchenne muscular dystrophy ahead of a hearing on the therapy. The latest review adds uncertainty for the company and for families following the development of another potential treatment in the rare disease space.
According to the agency, Capricor’s stem cell treatment did not meet the objectives of a Phase 3 trial. That assessment appears to conflict with the company’s more positive view of the data, setting up a sharper debate over whether the treatment shows enough benefit to move forward.
The dispute over efficacy is especially important because Duchenne muscular dystrophy is a serious inherited disorder with limited treatment options. In that context, regulatory decisions often draw close attention from patients, investors, and clinicians, particularly when a therapy reaches a late-stage review.
The FDA’s comments ahead of the hearing suggest the upcoming discussion may focus heavily on whether the trial results support the drug’s effectiveness. For Capricor, the agency’s stance marks another twist in a closely watched review process for a Duchenne therapy.
